Cellvie
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell
Cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT).
The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.
Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.
Visit website: https://cellvie.bio
Details last updated 16-Sep-2022
People at Cellvie
Cellvie News
cellvie closes $5.5 million of financing to develop its allogeneic mitochondria therapies
KIZOO Technology Ventures - 06-Feb-2023
Mitochondria dysfunction is linked to several ageing-related diseases, including neurodegeneration, so a big potential market
Read more...Reason reports back from October's Rejuvenation Startup Summit
Fight Aging! - 19-Oct-2022
Some really exciting developments with quite a few in clinical trials
Read more...Longevity Technology interviews cellvie CEO, Alex Schueller, about therapeutic mitochondria
Longevity Technology - 14-Sep-2022
Initially targeting ischemia-reperfusion injury, TMT has potential to treat multiple age-related diseases
Read more...